Ascendis’ Yorvipath (palopegteriparatide) Receives the EC’s Approval for the Treatment of Chronic Hypoparathyroidism
Shots:
- The approval was granted following the CHMP’s positive opinion for Yorvipath adopted earlier on Sep’23. The CHMP positive opinion and recommendation for approval was granted to Yorvipath by the name TransCon PTH (palopegteriparatide) as a parathyroid hormone (PTH) replacement therapy for the treatment of adults with chronic hypoparathyroidism
- The CHMP positive opinion was granted based on the data from the P-III (PaTHway) & P-II (PaTH Forward) clinical trials evaluating TransCon PTH in patients with hypoparathyroidism
- TransCon PTH, to be marketed in the EU as Yorvipath, is a prodrug of parathyroid hormone (PTH 1-34) indicated to be administered QD. Moreover, the company plans to launch Yorvipath initially in Germany by Jan’24
Ref: Globenewswire | Image: Ascendis Pharma
Related News:- Ascendis Pharma Receives the EMA’s CHMP Positive Opinion of TransCon PTH (palopegteriparatide) for Chronic Hypoparathyroidism
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
